Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

From the Desk of Avigdor Kaplan, PhD

Avigdor Kaplan
Director General, Hadassah Medical Organization

Dear Hadassah Family,

It has been two months since I began serving as Director General of the Hadassah Medical Organization; two months of concentrated effort, two months of difficult decisions and two months of continuing to learn more about the Medical Center.

During these two months, I have often thought about my very personal connection to Hadassah and the tremendous impact its life-saving treatment and groundbreaking research has had on my life and the lives of people I love. Almost everyone I know or meet has a "Hadassah story." Mine centers on a close relative, a 26-year-old I will call Yael, who had been married a year when all this took place.

For Americans, July 4th is an especially meaningful date; for this Israeli, it is as well. On July 4th 1990, Yael received a bone marrow transplant from her younger sister at Hadassah. It was the only possible cure for her very aggressive cancer of the blood and bone marrow. There was – and still is – no treatment for her disease. Bone marrow transplantation from a matching donor was – and still is – the only hope.

Before the transplant even took place, Yael received high doses of chemotherapy and radiation of her entire body to prepare her for the procedure. Probably the most significant aspect of the preparation treatment was an innovative new technique that was developed by Hadassah's bone marrow transplant team. Called total lymphoid irradiation, it was administered to generate a novel way of suppressing her immune system to help ensure that her body would not reject her sister's cells.

To also help prevent the severe post-transplant complication known as graft versus host disease (GVHD), Yael was enrolled in an unusual clinical trial where the bone marrow she was about to receive was treated before it was transplanted. Hadassah's unique approach was recognized by the scientific world as T-cell repletion therapy for the induction of Graft vs. Leukemia effect.

The transplant and subsequent innovative cell therapy entirely eliminated Yael's aggressive leukemia. After 80 days of hospitalization at Hadassah, we were overjoyed when this now healthy young woman returned home. And although it was considered a highly unlikely possibility, she subsequently became pregnant and gave birth to a healthy child; a miracle that was followed by the birth of two more healthy children.

A little over a year ago, a seven-year-old girl's life was saved with another Hadassah innovative procedure – an outgrowth of outstanding research on the use of enhanced placental-derived Mesenchymal Stem Cells (MSCs) to combat Graft-versus-Host Disease. That achievement was followed by two other successful procedures – on a young woman and a 45-year-old man. Prof. Reuven Or, Head of our Department of Bone Marrow Transplantation and Cancer Immunology, received special permission from the Ministry of Health to administer the vital treatment, which is based on Hadassah research and ongoing collaboration with Pluristem Therapeutics, an Israeli biotech company.

"One of the many obstacles to bone marrow transplantation is still GVHD," he says. "Once it develops it is very difficult to treat. I believe that the use of MSCs to treat resistant GVHD is a breakthrough that will move us forward. The current treatment, the use of immune suppressants, is very toxic and opens the door to very invasive infections." Using MSCs that were produced at Hadassah in Prof. Or's lab, the concept was tested and proved in 2007.

"The placenta is a miraculous machine of nature," Prof. Or says, pointing out that it allows the ultimate mismatch of foreign bodies, the introduction of a fetus into the mother's womb. "The placenta supports building the body tissue and inducing immuno-modulation to prevent rejection," he explains.

Last month, Prof. Or and his team announced another research breakthrough. In a project conducted with Yale University and Bio-Incept, an American biotechnology company, they proved that a peptide released by a fetus during pregnancy effectively prevents GVHD in mice, following a bone marrow transplant. The peptide, labeled "pre-implantation factor" (PIF), is released during its early stages of development, enabling it to become safely implanted in the mother's uterus. Prof. Or and his team have already proved that the peptide treatment has no toxic or negative side effects in healthy animals and are now preparing to conduct clinical trials in humans. This research complements other studies conducted by the Department of Bone Marrow Transplantation that demonstrated the effectiveness of the peptide in preventing diabetes and central nervous system inflammation.

I joined you in the Hadassah family so that together we could continue to do what we do best – provide outstanding patient care and produce lifesaving medical research for all the Yaels' in the world.

Avigdor Kaplan, PhD

Date: 7/31/2013

Hadassah Stem Cell Expert Speaks at TEDx Conference in Jaffa

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Hadassah Physicians Receive Prestigious Grants and Awards

New Research at Hadassah: Computational Tools Unravel the Mystery of Transient Amnesia

From Life-Threatening Brain Bleed to Birth of a Daughter

Cookbook Author, Rabbi Marks, Spends Last Days at Hadassah's Hospice

Hadassah’s Revolutionary Tipat Halav Clinics of 1920s Featured in Jerusalem Old City Museum

Victims of Terror Share Their Stories of Anguish and Appreciation with Hadassah President

Hadassah’s Advanced Gene Sequencing Changes the Life of a Family from Uzbekistan

IDF Medic Heroically Battles Terrorist, Both Treated at Hadassah

Orthopedic Trauma Turns Tragedy into Innovation at Hadassah

On the Cutting-Edge of Melanoma Treatment: Hadassah’s Protocols and Research

Saving a Newborn from a Life Without Sight

Terrorist and Victim Sent to Hadassah's Hospitals After Third Attack in Two Weeks

Three Sent to Hadassah After Second Jerusalem Terror Attack of the Week

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

“We Don’t Say ‘No’,” Hadassah Neurosurgeon Explains in Operating on 82-Year-Old Patient

Cutting-Edge Medicine and Research; a Role Model for Peace: A Briefing from the Hospital's Director General

4 Ways Hadassah Hospital is Preparing for Ebola—Just in Case

Hailing from 17 Countries: the 39th Graduation Class of Hadassah’s International Master of Public Health Program

More hMedicine Stories

Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America